As a significant number of drugs fail to reach the market owing to poor bioavailability, Lexaria Bioscience Corp. (NASDAQ: LEXX) is among those companies exploring different tools and methods to try to solve the problem. Lexaria is currently leading the industry in terms of innovation in drug delivery platforms. “Its patented DehydraTECH(TM) technology is specifically designed to improve how active pharmaceutical ingredients (‘APIs’) enter the bloodstream, ultimately increasing the effectiveness of fat-soluble molecules,” reads a recent article. The piece discusses Lexaria’s DehydraTECH as a product of years of research and millions in investments. Currently, the technology is covered by 23 issued and over 50 pending patents in 40 different countries around the world. “Lexaria remains committed to exploring new ways through which its DehydraTECH technology can help even more people. So far, it is investigating new products for hypertension, anti-viral treatments, oral nicotine and other drug classes, with notable progress made so far. The company is also conducting research and development on several critical indications, including epilepsy, dementia, rheumatoid disease, diabetes, human hormones, Ibuprofen and Naproxen (‘NSAIDs’), and PDE5 inhibitors. . . Lexaria understands the value and usefulness of its technology, hence its commitment to further research and partnering with other strategic players within the industry. Its efforts improve the bioavailability of pharmaceuticals and therapeutics, one drug class at a time.”
To view the full article, visit https://cnw.fm/21CXH
About Lexaria Bioscience Corp.
Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce time of onset from one to two hours to minutes, and mask unwanted tastes. The technology is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 23 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
